Browsing: Enfortumab

The European Commission has approved enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for the treatment of adult patients with…

Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) had superior overall survival (OS) vs platinum-based chemotherapy in patients with previously untreated locally…

Updated 3.5-year follow-up results from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856) demonstrated that the combination of enfortumab vedotin (Padcev) plus…

Perioperative treatment with durvalumab (Imfinzi) in combination with neoadjuvant enfortumab vedotin-ejfv (EV; Padcev) demonstrated statistically significant and clinically meaningful improvements…

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for…

Findings from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124) revealed significant improvements in event-free survival (EFS), overall survival (OS), and pathological…